This randomized clinical trial studies the Beating Lung Cancer in Ohio protocol in improving survival in patients with stage IV non-small cell lung cancer. The Beating Lung Cancer in Ohio protocol may help in evaluating immunotherapies and targeted therapies that prolong survival, have more favorable toxicity profiles than conventional chemotherapy and impact quality of life.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Cost-Effectiveness Analysis
Timeframe: Up to 24 months
Overall survival (Aim I observational phase)
Timeframe: Up to 3 years
Percent of patients receiving first line targeted therapy (Aim I observational phase)
Timeframe: Up to 3 years
Percent of patients receiving genomic testing at diagnosis and type of genomic testing (Aim I observational phase)
Timeframe: Up to 3 years
Percent of patients receiving genomic testing later in treatment (Aim I observational phase)
Timeframe: Up to 3 years
Percent of patients receiving off label therapy (Aim I observational phase)
Timeframe: Up to 3 years
Percent of patients referred to clinical trials (Aim I observational phase)
Timeframe: Up to 3 years
The Ohio State University Comprehensive Cancer Center
Percent of patients who enroll in therapeutic clinical trials (Aim I observational phase)
Timeframe: Up to 3 years
Progression free survival (Aim I observational phase)
Timeframe: Up to 3 years
Quality of life assessed using European Organization for Research and Treatment-quality of life questionnaire
Timeframe: Up to 24 months
Smoking cessation (Aim III centralized telephone counseling/decision support)
Timeframe: Up to 6 months
Survival (Aim 2 advanced genomic and immunotherapy testing/decision support)
Timeframe: Up to 3 years